Short answer
Beam Therapeutics Inc. (BEAM) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $32M (up 324.9% year over year) with net income of −$94M.
Q1 2026 key financials · XBRL
- Revenue
- $32M
- +324.9% YoY
- Net income
- −$94M
- +13.7% YoY
- Operating margin
- -337.8%
- EPS (diluted)
- −$0.91
- +26.6% YoY
Source: XBRL data from the Beam Therapeutics Inc. (BEAM) Q1 2026 10-Q on SEC EDGAR. USD.
Beam Therapeutics Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No explicit 10-Q risk-factor changes provided; filing text is truncated before the formal section
- Clinical development risk: BEAM-302 multi-dose cohort included Grade 4 ALT and Grade 3 AST elevations
- Regulatory risk: BEAM-302 accelerated approval depends on FDA acceptance of a 12-month biomarker endpoint
- Operational risk: risto-cel manufacturing requires a median three collection days per patient
- Financial risk: $1.7 billion accumulated deficit and continued need for additional capital at March 31, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Beam Therapeutics Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.